Breakthrough trial tests promising new treatment for aggressive breast cancer
NCT ID NCT06057610
Summary
This study compares a new drug combination (SHR-A1811 with or without pertuzumab) against the current standard treatment for HER2-positive breast cancer that has returned or spread. The trial involves 868 women with advanced breast cancer to see if the new approach helps patients live longer without their cancer worsening. Researchers will measure how long patients remain progression-free and monitor safety throughout the study.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-POSITIVERECURRENT OR METASTATIC BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
The First Affiliated Hospital of Nanjing Medical University
Nanjing, Jiangsu, 210029, China
Conditions
Explore the condition pages connected to this study.